Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Hyphens Pharma International Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 3/6

Hyphens Pharma International yıllık ortalama 11.1% oranında kazançlarını artırırken, Pharmaceuticals sektöründe kazançlar growing at 10.5% annual. Gelirler growing yılda ortalama 9.9% oranında artmaktadır. Hyphens Pharma International'in özkaynak karlılığı 15.8% ve net marjı 5.3%'dir.

Anahtar bilgiler

11.1%

Kazanç büyüme oranı

10.9%

EPS büyüme oranı

Pharmaceuticals Sektör Büyümesi	12.4%
Gelir büyüme oranı	9.9%
Özkaynak getirisi	15.8%
Net Marj	5.3%
Son Kazanç Güncellemesi	30 Jun 2024

Yakın geçmiş performans güncellemeleri

Recent updates

Gelir ve Gider Dağılımı

Hyphens Pharma International nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

Catalist:1J5 Gelir, gider ve kazançlar (SGD Millions )
Tarih	Gelir	Kazançlar	G+A Giderleri
30 Jun 24	196	10	52
31 Mar 24	185	10	50
31 Dec 23	171	9	50
30 Sep 23	156	7	48
30 Jun 23	156	9	48
31 Mar 23	156	10	48
31 Dec 22	162	11	48
30 Sep 22	156	12	40
30 Jun 22	143	9	43
31 Mar 22	132	8	40
31 Dec 21	126	7	40
30 Sep 21	126	6	37
30 Jun 21	123	6	39
31 Mar 21	126	6	37
31 Dec 20	121	6	37
30 Sep 20	126	7	36
30 Jun 20	125	8	36
31 Mar 20	124	7	35
31 Dec 19	119	7	35
30 Sep 19	117	6	33
30 Jun 19	115	5	32
31 Mar 19	117	5	32
31 Dec 18	121	5	31
30 Sep 18	117	5	32
30 Jun 18	117	6	30
31 Mar 18	115	6	29
31 Dec 17	113	6	29
31 Dec 16	101	5	29
31 Dec 15	78	5	19

Kaliteli Kazançlar: 1J5 yüksek düzeyde nakit dışı kazança sahiptir.

Büyüyen Kar Marjı: 1J5 'nin mevcut net kar marjları (5.3%) geçen yılın (5.6%) değerinden daha düşüktür.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: 1J5 şirketinin kazancı son 5 yılda yılda 11.1% oranında arttı.

Büyüme Hızlandırma: 1J5 'un son bir yıldaki kazanç büyümesi ( 18.9% ) 5 yıllık ortalamasını (yıllık 11.1% ) aşıyor.

Kazançlar vs. Sektör: 1J5 geçen yılki kazanç büyümesi ( 18.9% ) Pharmaceuticals sektörünün 6.4% değerini aştı.

Özkaynak Getirisi

Yüksek ROE: 1J5 'nin Özsermaye Getirisi ( 15.8% ) düşük olarak değerlendiriliyor.

Hyphens Pharma International Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 3/6

Anahtar bilgiler

Yakın geçmiş performans güncellemeleri

First quarter 2024 earnings released

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Third quarter 2023 earnings released

Second quarter 2023 earnings released

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Full year 2022 earnings released: EPS: S$0.037 (vs S$0.023 in FY 2021)

Recent updates

Hyphens Pharma International Limited Launches Ceradan Advanced Hand Balm, Specially Designed for Hand Eczema

Price target increased by 7.1% to S$0.38

First quarter 2024 earnings released

Hyphens Pharma International Limited Approves a Final Tax Exempt (One-Tier) Dividend for the Financial Year Ended 31 December 2023

Final dividend of S$0.0086 announced

Hyphens Pharma International Limited, Annual General Meeting, Apr 25, 2024

Consensus revenue estimates increase by 10%

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Insufficient new directors

Third quarter 2023 earnings released

Price target decreased by 10% to S$0.34

Hyphens Pharma International Limited Announces Special Interim Tax Exempt (One-Tier) Dividend for the Financial Year Ending 31 December 2023, Paid on 31 August 2023

Second quarter 2023 earnings released

Hyphens Pharma International Limited Appoints Zhang Yufan as Chief Financial Officer

Price target decreased by 8.9% to S$0.39

Now 23% undervalued after recent price drop

Upcoming dividend of S$0.011 per share at 3.3% yield

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Consensus EPS estimates increase by 14%

Full year 2022 earnings released: EPS: S$0.037 (vs S$0.023 in FY 2021)

Hyphens Pharma International Limited Launches its New Product, Meradan® Cream ("Meradan®") in Indonesia

Price target increased to S$0.41

Insufficient new directors

Price target increased to S$0.41

Consensus EPS estimates increase by 12%

Second quarter 2022 earnings released

Insufficient new directors

Hyphens Pharma International Limited Approves Final Exempt (One-Tier) Dividend for the Year Ended 31 December 2021, Payable on 25 May 2022

Price target decreased to S$0.35

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Hyphens Pharma International Limited, Annual General Meeting, Apr 27, 2022

Hyphens Pharma International Limited Recommends Final Tax Exempt (1-Tier) Dividend for the Financial Year Ended December 31, 2021

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased to S$0.35

Third quarter 2021 earnings released: EPS S$0.004 (vs S$0.003 in 3Q 2020)

First quarter 2021 earnings released: EPS S$0.007 (vs S$0.007 in 1Q 2020)

Hyphens Pharma International Limited Approves Final Exempt (One-Tier) Dividend for the Year Ended 31 December 2020, Payable on 25 May 2021

Full year 2020 earnings released: EPS S$0.021 (vs S$0.022 in FY 2019)

Full year 2020 earnings released: EPS S$0.021 (vs S$0.022 in FY 2019)

Revenue and earnings miss expectations

Hyphens Pharma International Limited Appoints Exclusive Distributor in South Korea for Tdf Fairence T-Complex

New 90-day low: S$0.32

Price target lowered to S$0.38

New 90-day low: S$0.34

Hyphens Pharma International Limited Announces Board Changes

Analysts update estimates

First half earnings released

Gelir ve Gider Dağılımı

Kazanç ve Gelir Geçmişi

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Özkaynak Getirisi

Varlık Getirisi

Kullanılan Sermaye Getirisi

Geçmişte güçlü performans gösteren şirketleri keşfedin